FDA-cleared digital ADHD therapy device built against the new 2026 CMS DMHT reimbursement codes

“CMS's CY 2026 PFS final rule expanded DMHT payment to FDA-cleared/authorized ADHD devices, while declining GI and fibromyalgia coverage (https://www.sidley.com/en/insights/newsupdates/2025/11/cms-finalizes-key-medicare-reimbursement-policies-for-telehealth-chronic-disease-and-di…”